179 related articles for article (PubMed ID: 27456539)
1. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.
Apostolidis L; Bergmann F; Jäger D; Winkler EC
Cancer Med; 2016 Sep; 5(9):2261-7. PubMed ID: 27456539
[TBL] [Abstract][Full Text] [Related]
2. Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.
Yeung HM; Sreekrishnanilayam K; Meeker C; Deng M; Agrawal S; Abdullah H; Vijayvergia N
J Gastrointest Cancer; 2023 Mar; 54(1):73-79. PubMed ID: 35006522
[TBL] [Abstract][Full Text] [Related]
3. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
[TBL] [Abstract][Full Text] [Related]
4. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Lv C; Liu X; Zheng Q; Chen H; Yang X; Zhong J; Wang Y; Duan J; Wang Z; Bai H; Wu M; Zhao J; Wang J; Wang Z; An T; Zhuo M
Thorac Cancer; 2018 Sep; 9(9):1166-1173. PubMed ID: 30058109
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
Lycan TW; Pardee TS; Petty WJ; Bonomi M; Alistar A; Lamar ZS; Isom S; Chan MD; Miller AA; Ruiz J
PLoS One; 2016; 11(10):e0164244. PubMed ID: 27732654
[TBL] [Abstract][Full Text] [Related]
6. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas.
Chen MH; Chou WC; Hsiao CF; Jiang SS; Tsai HJ; Liu YC; Hsu C; Shan YS; Hung YP; Hsich CH; Chiu CH; Liu TC; Cho SF; Liu TW; Chao Y
Oncologist; 2020 May; 25(5):e782-e788. PubMed ID: 31852810
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
8. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
Hadoux J; Malka D; Planchard D; Scoazec JY; Caramella C; Guigay J; Boige V; Leboulleux S; Burtin P; Berdelou A; Loriot Y; Duvillard P; Chougnet CN; Déandréis D; Schlumberger M; Borget I; Ducreux M; Baudin E
Endocr Relat Cancer; 2015 Jun; 22(3):289-98. PubMed ID: 25770151
[TBL] [Abstract][Full Text] [Related]
9. Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Gonzalez EE; Villanueva N; Fra J; Berros JP; Jimenez P; Luque M; Muñiz I; Blay P; Fernandez Y; Vieitez JM; Muriel C; Sanmamed M; Coto PP; Izquierdo M; Estrada E; Lacave AJ
Invest New Drugs; 2011 Dec; 29(6):1459-64. PubMed ID: 20464446
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
McGarrah PW; Leventakos K; Hobday TJ; Molina JR; Finnes HD; Westin GF; Halfdanarson TR
Pancreas; 2020 Apr; 49(4):529-533. PubMed ID: 32282766
[TBL] [Abstract][Full Text] [Related]
11. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
Allen JW; Moon J; Redman M; Gadgeel SM; Kelly K; Mack PC; Saba HM; Mohamed MK; Jahanzeb M; Gandara DR
J Clin Oncol; 2014 Aug; 32(23):2463-70. PubMed ID: 25002722
[TBL] [Abstract][Full Text] [Related]
12. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
[TBL] [Abstract][Full Text] [Related]
16. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]